Company Filing History:
Years Active: 2004
Title: Jack D. Burton: Innovator in Targeted Drug Delivery
Introduction
Jack D. Burton is a notable inventor based in Long Island City, NY (US). He has made significant contributions to the field of molecular medicine, particularly in the area of targeted drug delivery. His innovative approach aims to enhance the efficacy of therapeutic agents in treating malignancies and inflammatory conditions.
Latest Patents
Jack D. Burton holds a patent for an invention titled "Antibody/receptor targeting moiety for enhanced delivery of armed ligand." This patent describes a method for the intracellular delivery of drugs or other agents for diagnosis and therapy. The invention utilizes a targeting moiety of an antibody and the ligand-binding region of a selected cytokine receptor. This targeting moiety specifically targets surface antigens on a designated cell population. The method involves administering the targeting moiety to a subject, followed by the delivery of therapeutic or diagnostic agents linked to the cognate cytokine after a specified interval. This invention provides rapid and efficient internalization of the cytokine receptor antibody/antigen complexes, significantly increasing the number of cytokine receptors on the cell surface.
Career Highlights
Jack D. Burton is associated with the Center for Molecular Medicine and Immunology, where he continues to advance research in targeted therapies. His work focuses on improving the delivery mechanisms of therapeutic agents, which is crucial for enhancing treatment outcomes in patients.
Collaborations
Jack collaborates with David M. Goldenberg, a fellow innovator in the field. Their partnership aims to push the boundaries of current medical treatments and improve patient care through innovative solutions.
Conclusion
Jack D. Burton's contributions to targeted drug delivery represent a significant advancement in medical science. His innovative methods have the potential to transform the way therapies are administered, leading to better outcomes for patients with malignancies and inflammatory conditions.